Hyperhomocysteinemia and lower extremity wounds

International Journal of Lower Extremity Wounds

Volumn 7, Issue 3, 2008, Pages 126-136

  Schwartzfarb, Elissa M ^a   Romanelli, Paolo ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Folic acid; Foot ulcer; Hyperhomocysteinemia; Leg ulcer; Venous insufficiency; Vitamin B12

Indexed keywords

HOMOCYSTEINE;

ARTERY DISEASE; ARTERY THROMBOSIS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE MARKER; FOOT ULCER; HISTOPATHOLOGY; HUMAN; HYPERHOMOCYSTEINEMIA; LEG ULCER; LOWER LEG; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VEIN INSUFFICIENCY; VEIN THROMBOSIS;

BLOOD COAGULATION; ENDOTHELIUM, VASCULAR; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LOWER EXTREMITY; MYOCYTES, SMOOTH MUSCLE; PLATELET AGGREGATION; RISK FACTORS; VARICOSE ULCER; WOUNDS AND INJURIES;

EID: 49749131184     PISSN: 15347346     EISSN: 15526941     Source Type: Journal    
DOI: 10.1177/1534734608322490     Document Type: Review

References (108)

1. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995 ; 274 ; 1049-1057.
2. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997 ; 277: 1775-1781.
3. Wald DS, Law M., Morris JK Homocysteine and cardiovascular disease: evidence of causality from a meta-analysis. BMJ. 2002 ; 325 ; 1202-1209.
4. Hackam DG, Anand SS Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA. 2003 ; 290: 932-940.
5. McCully KS Vascular pathology of homocysteinemia: implications for pathogenesis of atherosclerosis. Am J Pathol. 1969 ; 56: 111-128.
6. Ueland PM, Refsum H., Beresford SA, Vollset SE The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr. 2000 ; 72: 324-332.
7. Mekkes JR, Loots MA, Van Der Wal AC, Bos JD Causes, investigation and treatment of leg ulceration. Br J Dermatol. 2003 ; 148: 388-401.
8. Finklestein JD Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost. 2000 ; 26: 219-225.
9. Selhub J. Homocysteine metabolism. Annu Rev Nutr. 1999 ; 19: 217-246.
10. Ueland PM, Refsum H., Stabler SP, Malinow MR, Andersson A., Allen RH Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 1993 ; 39: 1764-1779.
11. Castro R., Rivera U., Blom HJ, et al. Homocysteine metabolism, hyperhomocysteinemia and vascular disease: an overview. J Inherit Metab Dis. 2006 ; 29: 3-20.
12. Refsum H., Guttormsen AB, Fiskerstrand T., Ueland PM Hyperhomocysteinaemia in terms of steady-state kinetics. Eur J Pediatr. 1998 ; 157: S45 - S49.
13. Kraus JP, Janosík M., Kozich V., et al. Cystathionine beta-synthase mutations in homocystinuria. Hum Mutat. 1999 ; 13: 362-375.
14. Goyette P., Sumner JS, Milos R., et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet. 1994 ; 7: 195-200.
15. Blom HJ Genetic determinants of hyperhomocysteinaemia: the roles of cystathionine beta-synthase and 5,10-methylenetetrahydrofolate reductase. Eur J Pediatr. 2000 ; 159: S208 - S212.
16. Watkins D., Ru M., Hwang HY, et al. Hyperhomocysteinemia due to methionine synthase deficiency, cblG: structure of the MTR gene, genotype diversity, and recognition of a common mutation, P1173L. Am J Hum Genet. 2002 ; 71: 143-153.
17. Kang SS, Zhou J., Wong PW, Kowalisyn J., Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 1988 ; 43: 414-421.
18. Klerk M., Verhoef P., Clarke R., et al. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002 ; 288: 2023-2031.
19. Ubbink JB, Vermaak WJ, van der Merwe A., Becker PJ Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 1993 ; 57: 47-53.
20. Selhub J., Jacques PF, Rosenberg IH, et al. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med. 1999 ; 131: 331-339.
21. Graham IM, O'Callaghan P. Vitamins, homocysteine and cardiovascular risk. Cardiovasc Drugs Ther. 2002 ; 16: 383-389.
22. Selhub J., Jacques PF, Wilson PWF, Rush D., Rosenberg IH Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993 ; 270: 2693-2698.
23. Bostom AG, Culleton BF Hyperhomocysteinaemia in chronic renal disease. J Am Soc Nephrol. 1999 ; 10: 891-900.
24. Wollesen F., Brattström L., Refsum H., Ueland PM, Berglund L., Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int. 1999 ; 55: 1028-1035.
25. Nedrebø BG, Ericsson UB, Nygård O., et al. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism. 1998 ; 47: 89-93.
26. van Guldener C., Stehouwer CD Diabetes mellitus and hyperhomocysteinemia. Semin Vasc Med. 2002 ; 2: 87-95.
27. Alcasabas P., Ravindranath Y., Goyette G., et al. 5,10- Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and the risk of acute lymphoblastic leukemia (ALL) in Filipino children. Pediatr Blood Cancer. 2008 ; 51: 178-182.
28. Refsum H., Smith AD, Ueland PM, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem. 2004 ; 50: 3-32.
29. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 ; 362: 801-809.
30. Harker LA, Ross R., Slichter SJ, Scott CR Homocysteine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 1976 ; 58: 731-741.
31. Wall RT, Harlan JM, Harker LA, Striker GE Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res. 1980 ; 18: 113-121.
32. Blundell G., Jones BG, Rose FA, Tudball N. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis. 1996 ; 122: 163-172.
33. Tawakol A., Omland T., Gerhard M., Wu JT, Creager MA Hyperhomocyst(e) inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 1997 ; 95: 1119-1121.
34. Wang J., Dudman NPB, Wilcken DE Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells. Thromb Haemost. 1993 ; 70: 1047-1052.
35. Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab. 2005 ; 6: 27-36.
36. Stamler JS, Osborne JA, Jaraki O., et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993 ; 91: 308-318.
37. Upchurch GR Jr, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 1997 ; 272: 17012-17017.
38. Loscalzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest. 1996 ; 98: 5-7.
39. Parthasarathy S. Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochem Biophys Acta. 1987 ; 917: 337-340.
40. Papatheodorou L., Weiss N. Vascular oxidant stress and inflammation in hyperhomocysteinemia. Antioxid Redox Signal. 2007 ; 9: 1941-1958.
41. Tyagi N., Ovechkin AV, Lominadze D., Moshal KS, Tyagi SC Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia. J Cell Biochem. 2006 ; 98: 1150-1162.
42. Chen C., Conklin BS, Ren Z., Zhong DS Homocysteine decreases endothelium-dependent vasorelaxation in porcine arteries. J Surg Res. 2002 ; 102: 22-30.
43. Abahji TN, Nill L., Ide N., Keller C., Hoffmann U., Weiss N. Acute hyperhomocysteinemia induces microvascular and macrovascular endothelial dysfunction. Arch Med Res. 2007 ; 38: 411-416.
44. Rudijanto A. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med Indones. 2007 ; 39: 86-93.
45. Tsai JC, Perrella MA, Yoshizumi M., et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to athersoclerosis. Proc Natl Acad Sci U S A. 1994 ; 91: 6369-6373.
46. Carmody BJ, Arora S., Avena R., Cosby K., Sidawy N. Folic acid inhibits homocytsiene-induced proliferation of human arterial smooth muscle cells. J Vasc Surg. 1999 ; 30: 1121-1128.
47. Chen C., Halkos ME, Surowiec SM, Conklin BS, Lin PH, Lumsden AB Effects of homocysteine on smooth muscle cell proliferation in both cell culture and artery perfusion culture models. J Surg Res. 2000 ; 88: 26-33.
48. Bescond A., Augier T., Chareyre C., Garçon D., Hornebeck W., Charpiot P. Influence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem Biophys Res Commun. 1999 ; 263: 498-503.
49. Doronzo G., Russo I., Mattiello L., Trovati M., Anfossi G. Homocysteine rapidly increases matrix metalloproteinase-2 expression and activity in cultured human vascular smooth muscle cells. Role of phosphatidyl inositol 3-kinase and mitogen activated protein kinase pathways. Thromb Haemost. 2005 ; 94: 1285-1293.
50. Majors A., Ehrhart LA, Pezacka EH Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997 ; 17: 2074-2081.
51. Rasmussen LM, Hansen PR, Ledet T. Homocysteine and the production of collagens, proliferation and apoptosis in human arterial smooth muscle cells. APMIS. 2004 ; 112: 598-604.
52. den Heijer M., Koster T., Blom HJ, et al. Hyperhomocysteinaemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996 ; 334: 759-762.
53. D'Angelo A., Selhub J. Homocysteine and thrombotic disease. Blood. 1997 ; 90: 1-11.
54. Graeber JE, Slott JH, Ulane RE, Schulman JD, Stuart MJ Effect of homocysteine and homocystine on platelet and vascular arachidonic acid metabolism. Pediatr Res. 1982 ; 16: 490-493.
55. Di Minno G., Davì G., Margaglione M., et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucolsensitive mechanism. J Clin Invest. 1993 ; 92: 1400-1408.
56. Mohan IV, Jagroop IA, Mikhailidis DP, Stansby GP Homocysteine activates platelets in vitro. Clin Appl Thromb Hemost. 2008 ; 14: 8-18.
57. Durand P., Prost M., Blache D. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis. 1996 ; 121: 231-243.
58. Riba R., Nicolaou A., Troxler M., Homer-Vaniasinkam S., Naseem KM Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis. 2004 ; 175: 69-75.
59. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LJ, Rodgers GM Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb. 1993 ; 13: 1327-1333.
60. Nishinaga M., Ozawa T., Shimada K. Omocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest. 1993 ; 92: 1381-1386.
61. Ratnoff OD Activation of Hageman factor by L-homocystine. Science. 1968 ; 162: 1007-1009.
62. Rodgers GM, Kane WH Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 1986 ; 77: 1909-1016.
63. Rodgers GM, Conn MT Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 1990 ; 75: 895-901.
64. Lentz SR, Sadler JE Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 1991 ; 88: 1906-1914.
65. Binette TM, Taylor FB Jr, Peer G., Bajzar L. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Blood. 2007 ; 110: 3168-3175.
66. Hajjar KA Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest. 1993 ; 91: 2873-2879.
67. Tofler GH, D'Agostino RB, Jacques PF, et al. Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk. Thromb Haemost. 2002 ; 88: 799-804.
68. Sauls DL, Wolberg AS, Hoffman M. Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. J Thromb Haemost. 2003 ; 1: 300-306.
69. Sauls DL, Arnold EK, Bell CW, Allen JC, Hoffman M. Pro-thrombotic and pro-oxidant effects of diet-induced hyperhomocysteinemia. Thromb Res. 2007 ; 120: 117-126.
70. Ebbesen LS, Olesen SH, Kruhøffer M., Ingerslev J., rntoft TF. Folate deficiency induced hyperhomocysteinemia changes the expression of thrombosis-related genes. Blood Coagul Fibrinolysis. 2006 ; 17: 293-301.
71. Abbade LP, Lastoria S. Venous ulcer: epidemiology, physiopathology, diagnosis and treatment. Int J Dermatol. 2005 ; 44: 449-456.
72. Bhargava S., Parakh R., Manocha A., Ali A., Srivastava LM Prevalence of hyperhomocysteinemia in vascular disease: comparative study of thrombotic venous disease vis-a-vis occlusive arterial disease. Vascular. 2007 ; 15: 149-153.
73. Fermo I., Vigano'D'Angelo S., Paroni R., Mazzola G., Calori G., D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med. 1995 ; 123: 747-753.
74. Walker N., Rodgers A., Birchall N., Norton R., MacMahon S. Leg ulceration as a long-term complication of deep vein thrombosis. J Vasc Surg. 2003 ; 38: 1331-1335.
75. Scott TE, LaMorte WW, Gorin DR, Menzoian JO Risk factors for chronic venous insufficiency: a dual case-control study. J Vasc Surg. 1995 ; 22: 622-628.
76. Lee P., Prasad K. Hyperhomocysteinemia and venous thrombosis. Int J Low Extrem Wounds. 2002 ; 1: 4-12.
77. Krupa Shankar DS, Akhib S. Leg ulcers due to hyperhomocysteinemia. Indian J Dermatol Venereol Leprol. 2006 ; 72: 367-369.
78. Kolbach DN, Veraart JC, Hamulyák K., Spaapen LJ, Neumann HA Recurrent leg ulcers in a young man with hyperhomocysteinemia, factor V Leiden and impaired fibrinolysis. Acta Derm Venereol. 2002 ; 82: 52-54.
79. Erol A., Cinar MG, Can C., Olukman M., Ulker S., Ko?ay. Effect of homocysteine on nitric oxide production in coronary microvascular endothelial cells. Endothelium. 2007 ; 14: 157-161.
80. Didier AF, Tourand JP, Collet E., Dalac S., Becker F., Lambert D. Distal cutaneous necrosis, an unusual etiology: hyperhomocysteinemia. Ann Dermatol Venereol. 1999 ; 126: 822-825.
81. Combemale P., Amiral J., Estival JL, Dupin M., Chouvet B., Berruyer M. Cutaneous necrosis revealing the coexistence of an antiphospholipid syndrome with acquired protein S deficiency, factor V Leiden and hyperhomocysteinemia. Eur J Dermatol. 2002 ; 12: 278-282.
82. Baker SR, Stacey MC, Singh G., Hoskin SE, Thompson PJ Aetiology of chronic leg ulcers. Eur J Vasc Surg. 1992 ; 6: 245-251.
83. Dormandy J., Heeck L., Vig S. Predictors of early disease in the lower limbs. Semin Vasc Surg. 1999 ; 12: 109-117.
84. Malinow MR, Kang SS, Taylor LM, et al. Prevalence of hyperhomocyst(e) inemia in patients with peripheral arterial occlusive disease. Circulation. 1989 ; 79: 1180-1188.
85. Molgaard J., Malinow MR, Lassvik C., Holm AC, Upson B., Olsson G. Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication. J Intern Med. 1992 ; 231: 273-279.
86. Taylor LM Jr, DeFrang RD, Harris EJ Jr, Porter JM The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg. 1991 ; 13: 128-136.
87. Asfar S., Safar HA Homocysteine levels and peripheral arterial occlusive disease: a prospective cohort study and review of the literature. J Cardiovasc Surg (Torino). 2007 ; 48: 601-605.
88. Garofolo L., Barros N. Jr, Miranda F. Jr, D'Almeida V., Cardien LC, Ferreira SR Association of increased levels of homocysteine and peripheral arterial disease in a Japanese-Brazilian population. Eur J Vasc Endovasc Surg. 2007 ; 34: 23-28.
89. Yudkin JS How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ. 1993 ; 306: 1313-1318.
90. Rudy A., Kowalska I., Straczkowski M., Kinalska I. Homocysteine concentrations and vascular complications in patients with type 2 diabetes. Diabetes Metab. 2005 ; 31: 112-117.
91. de Luis DA, Fernandez N., Arranz ML, Aller R., Izaola O., Romero E. Total homocysteine levels relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of patients with diabetes mellitus type 2. J Diabetes Complications. 2005 ; 19: 42-46.
92. Agulló-Ortuño MT, Albaladejo MD, Parra S., et al. Plasmatic homocysteine concentration and its relationship with complications associated to diabetes mellitus. Clin Chim Acta. 2002 ; 326: 105-112.
93. Boykin JV Jr, Baylis C., Allen SK, et al. Treatment of elevated homocysteine to restore normal wound healing: a possible relationship between homocysteine, nitric oxide, and wound repair. Adv Skin Wound Care. 2005 ; 18: 297-300.
94. Boykin JV Jr, Shawler LG, Sommer VL, Crossland MC, Kalns JE Diabetes-impaired wound healing predicted by urinary nitrate assay: a preliminary, retrospective study. Wounds. 1999 ; 11: 62-69.
95. Stallmeyer B., Anhold M., Wetzler C., Kahlina K., Pfeilschifter J., Frank S. Regulation of eNOS in normal and diabetes-impaired skin repair: implications for tissue regeneration. Nitric Oxide. 2002 ; 6: 168-177.
96. Jorizzo JL Livedoid vasculopathy: what is it ? Arch Dermatol. 1998 ; 134: 491-493.
97. Callen JP Livedoid vasculopathy: what it is and how the patient should be evaluated and treated. Arch Dermatol. 2006 ; 142: 1481-1482.
98. Gibson GE, Li H., Pittelkow MR Homocysteinemia and livedoid vasculitis. J Am Acad Dermatol. 1999 ; 40 (2 Pt 1). 279-281.
99. Hairston BR, Davis MD, Pittelkow MR, Ahmed I. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol. 2006 ; 142: 1413-1418.
100. Rampf J., Sunderkötter C., Hirschfeld G., Scharffetter-Kochanek K., Weiss JM Methylenetetrahydrofolate reductase polymorphism associated with moderate hyperhomocysteinaemia in a patient with livedo vasculopathy: treatment with vitamin supplementation and low molecular weight heparin. Br J Dermatol. 2006 ; 155: 850-852.
101. Irani-Hakime NA, Stephan F., Kreidy R., Jureidini I., Almawi WY Livedoid vasculopathy associated with combined prothrombin G20210A and factor V (Leiden) heterozygosity and MTHFR C677T homozygosity [published online ahead of print March 23, 2008]. J Thromb Thrombolysis. doi:10.1007/s11239-008-0214-1.
102. Meiss F., Marsch WC, Fischer M. Livedoid vasculopathy. The role of hyperhomocysteinemia and its simple therapeutic consequences. Eur J Dermatol. 2006: 16: 159-162.
103. ASHG/ACMG statement. Measurement and use of total plasma homocysteine. Am J Hum Genet. 1998 ; 63: 1541-1543.
104. Homocysteine Lowering Trialists ' Collabotation. Lowering blood homocysteine with folic acid supplementation: meta-analysis of randomized trials. BMJ. 1998 ; 316: 894-898.
105. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized control trial. JAMA. 2004 ; 291: 565-575.
106. Bonaa KH, Njolstad I., Ueland PM, et al for Norvit. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006 ; 354: 1578-1588.
107. Lonn E., Yusuf S., Arnold MJ, et al for the Heart Outcomes Prevention Evaluation (HOPE) 2. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006 ; 354: 1567-1577.
108. Clarke R., Armitage J., Lewington S., et al for the B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J. 2006 ; 151: 282-287.